sheila RHEUMarampa
3 years 10 months ago
Dr. Ogdie proposes a whole-patient care approach to the treat-to-target strategy in SpA with QoL as the most important target.
#ACR22 @Rheumnow @rheumarhyme @trishiemd https://t.co/GjLt2Nym3I
Richard Conway RichardPAConway
3 years 10 months ago
Nestor et al. HCQ <5mg/kg day assoc increased hospitalisation for SLE flare. aOR 4.41 (95% CI 1.50-12.98) @RheumNow #ACR22 Abstr#1654 https://t.co/I4bTu2DWaR https://t.co/jpOwHUTenk
Richard Conway RichardPAConway
3 years 10 months ago
Tuttle et al. Phase 2 RCT of Peresolimab (PD-1 stimulator) in DMARD-IR RA. Evidence of efficacy. No new safety signals @RheumNow #ACR22 Abstr#L03 https://t.co/vhrmtGTjw1 https://t.co/k1LLk95bv1
TheDaoIndex KDAO2011
3 years 10 months ago
#ACR22 #GIO #Osteoporosis Guidelines Case:
"Young skeletons recover bone loss rapidly after GC are discontinued." In these pts, despite daily pred 10 mg/day, they just needs Ca/Vit D, lifestyle mod, and monitoring. @rheumnow https://t.co/a5DVZoB3l8
Aurelie Najm AurelieRheumo
3 years 10 months ago
A new murine model to study Pso and PsA!
Immunodeficient mice NSG-SGM3 🐁 injected w/ serum & PBMCs from Pso and/or PsA pts = pro & arthritis (same phenotype than pts)
Mice skin & synovia >effector memory CD8 T cell & < naïve
https://t.co/cxSvEZC9Ly
Abs#L04 #ACR22 @Rheumnow https://t.co/hfbtSsP3f8
TheDaoIndex KDAO2011
3 years 10 months ago
#ACR22 #GIOP Guidelines Case:
In pt < 40 yo who had renal transplant on 7.5 mg/day or higher with low Z score, consult mineral/metabolism expert but you can consider Rx. @rheumnow https://t.co/RJuRi7EPX1
sheila RHEUMarampa
3 years 10 months ago
Are we giving enough HCQ?🤔
Findings from the study of Dr J Nestor show that ⬇️dose HCQ (</= 5mkd or <400mg/day) is associated w/ ⬆️hospitalizations for #lupus (adj. OR 4.41; 3.48)
#ACR22 @RheumNow ABST#1654 @rheumarhyme #ACRBest https://t.co/XCoZgbdOim
TheDaoIndex KDAO2011
3 years 10 months ago
Is he the only one?
Dr. Stone shared that he kept his notes from internship and residency! I kept an old tshirt from college, but this is a new level. #ACR22 @rheumnow https://t.co/Wj9c2Uizxt
A new target for treatment in AxSpA is the dual inhibition of IL17A and IL17F (IL17A/F). IL17A is a key driver of the inflammation in the AxSpA and Psoriatic Arthritis (PsA). IL17A and its structurally related IL17F share biologic functional properties. Inhibition of both cytokines (IL17A/F) should result in a greater clinical benefit in AxSpA and PsA than IL17A inhibition alone.
Dr. John Cush RheumNow
3 years 10 months ago
RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Bristol-Myers Squibb. All content chosen by RheumNow & its Faculty.
Richard Conway RichardPAConway
3 years 10 months ago
Ozen et al. Safety Opioids vs NSAIDs in RA. Similar risks except 2-fold increase in VTE with opioids. @RheumNow #ACR22 Abstr#1646 https://t.co/kWBf8t4TFh https://t.co/dxKoilOhFX
Aurelie Najm AurelieRheumo
3 years 10 months ago
FORWARD databank RA
4500+ opioid & 11000+ NSAID
MACE 133 vs. 392 (18.2/1000 PY vs. 14.6/1000 PY)
Deaths 95 vs. 228 (12.6/1000 PY vs. 8.2/1000 PY)
IR MACE & mortality NSAID < Opioids
Driven by VTE > Opioids vs NSAIDs HR=2.45
https://t.co/fl7cJNGrvu
Abs#1646 #ACR22 @Rheumnow https://t.co/wV5hYMfYLl
Richard Conway RichardPAConway
3 years 10 months ago
Brooks et al. Risk lung cancer higher in RA (aHR 1.53) and RA-ILD (aHR 3.06) than controls. Persisted in non-smokers, non-RA-ILD, incident RA @RheumNow #ACR22 Abstr#1647 #ACRbest https://t.co/c18k9OLDIm https://t.co/UTgYZAmfmk
TheDaoIndex KDAO2011
3 years 10 months ago
Dr. B Humphrey #ACR22 #Osteoporosis Guidelines:
Treatment algorithms for GIO and in special populations (age < 18) @rheumnow https://t.co/dZ02kuOUeH
Richard Conway RichardPAConway
3 years 10 months ago
Juge @Juge_P_A @PhilippeDieude et al. Increased mortality in RA-ILD. HR 3.4 vs RA. <75 HR 4.8 . ILD first HR 8.4 @RheumNow #ACR22 Abstr#1959 #ACRbest https://t.co/mnbeBPuyC7 https://t.co/sLU2ZuTMw7
